-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Structure Therapeutics, Raises Price Target to $100

Benzinga·12/09/2025 19:40:22
Listen to the news
Citigroup analyst Samantha Semenkow maintains Structure Therapeutics (NASDAQ:GPCR) with a Buy and raises the price target from $60 to $100.